Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Cardiology · Takotsubo Cardiomyopathy

The Road to Healing: Treatment and Long-Term Recovery

At a Glance

Recovery from Takotsubo cardiomyopathy is typically excellent, with the heart's pumping function usually returning to normal within 4 to 8 weeks. Treatment focuses on supportive care, managing temporary complications, and using medications like beta-blockers or ACE inhibitors to aid healing.

The recovery journey from Takotsubo is often a source of great relief: for most patients, the heart muscle is not permanently damaged and will return to its normal strength [1]. However, the weeks following your hospital stay are a critical “healing window” where your medical team focuses on supportive care and confirming that your heart has fully bounced back [2][3].

Acute Care: Navigating the Obstacles

In the first few days, treatment is highly individualized. There is no single “Takotsubo pill”; instead, doctors manage the symptoms and complications your heart is experiencing [4].

Tailoring Treatment for LVOT Obstruction

If your heart’s shape caused a Left Ventricular Outflow Tract (LVOT) obstruction (a temporary blockage of blood leaving the heart), your medical team will carefully select your medications [5].

  • Instead of using standard heart-stimulating drugs (which can sometimes make the temporary obstruction worse), doctors often use intravenous (IV) fluids to “fill” the heart [6][7].
  • They may also use beta-blockers to slow the heart rate, which gently helps clear the obstruction and stabilize blood pressure [8][9]. Knowing that doctors are carefully monitoring your specific heart shape ensures you are getting the safest care.

The Road to Recovery: 4 to 8 Weeks

The hallmark of Takotsubo is its transient nature. Unlike a heart attack, where muscle death is permanent, the “stunned” cells in Takotsubo usually recover their full pumping power [10][2].

  • Ejection Fraction (LVEF): This is a measurement of how much blood your heart pumps out with each beat. Most patients see their LVEF return to a normal range (55% or higher) within 2 months [2][3].
  • The Follow-Up Echo: You must have a follow-up echocardiogram or Cardiac MRI scheduled for 4 to 8 weeks after your event [11]. This is the only way for your doctor to confirm the “ballooning” has resolved and your heart has regained its shape [1].
  • Lingering Effects: Even after your pumping strength returns to normal, some cellular-level changes in how your heart handles calcium and energy may persist for 3 months or longer [12]. This explains why many patients feel lingering fatigue even after being told their heart looks “fine” on an ultrasound. Your fatigue is real and a normal part of the healing process.

Long-Term Medications and Prevention

Because the evidence for Takotsubo is still evolving, there is no universal consensus on long-term medication [4][13]. Your doctor will likely tailor your prescriptions based on your specific health history.

  • ACE Inhibitors / ARBs: These medications support heart remodeling and lower blood pressure [14]. Some data suggest they may help prevent the condition from returning, though more study is needed [14][15].
  • Beta-Blockers: These help lower the heart’s sensitivity to adrenaline (stress hormones) [16]. While they may not completely prevent a future “broken heart” episode, they are frequently used for overall heart protection [16][15].

The most important “treatment” for the long term is identifying and managing your triggers, which you can read more about in Life After a Broken Heart.

Common questions in this guide

How long does it take to recover from Takotsubo cardiomyopathy?
Most patients see their heart's pumping power, or ejection fraction, return to a normal range within 4 to 8 weeks. However, you may experience lingering fatigue for three months or longer as your heart cells fully heal on a microscopic level.
What is LVOT obstruction in Takotsubo?
Left Ventricular Outflow Tract (LVOT) obstruction is a temporary blockage of blood leaving the heart, caused by the heart's changed shape. Doctors manage this by carefully using IV fluids and beta-blockers instead of standard heart-stimulating drugs.
What medications are prescribed after Takotsubo cardiomyopathy?
Doctors often prescribe ACE inhibitors, ARBs, and beta-blockers during recovery. These medications help lower blood pressure, support the heart's healing process, and reduce the heart's sensitivity to stress hormones.
Will I need follow-up heart tests after going home?
Yes, you will need a follow-up echocardiogram or cardiac MRI about 4 to 8 weeks after your initial event. This follow-up imaging is essential to confirm that the temporary ballooning has resolved and your heart has regained its normal shape.
Why do I still feel tired even though my heart ultrasound is normal?
Even after your heart's pumping strength returns to normal on an ultrasound, cellular-level changes in how your heart handles energy can persist. This lingering fatigue is a real and normal part of the healing process that can last for several months.

Get notified when new evidence is published on Tako-Tsubo cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    [Takotsubo cardiomyopathy].

    Dujardin JJ, Belle L, Yayehd K, Georges JL

    La Revue du praticien 2019; (69(8)):877-880.

    PMID: 32237653
  2. 2

    Temporarily increased stroke rate after Takotsubo syndrome: need for an anticoagulation?

    Abanador-Kamper N, Kamper L, Wolfertz J, et al.

    BMC cardiovascular disorders 2018; (18(1)):117 doi:10.1186/s12872-018-0842-0.

    PMID: 29907089
  3. 3

    Novel Understanding of Takotsubo Syndrome.

    Watanabe M, Izumo M, Akashi YJ

    International heart journal 2018; (59(2)):250-255 doi:10.1536/ihj.17-586.

    PMID: 29503405
  4. 4

    Is modulation (desensitization) of the beta-adrenergic receptors a cause or an epiphenomenon of takotsubo syndrome?

    Madias JE

    Journal of cardiology 2021; (77(5)):552 doi:10.1016/j.jjcc.2021.01.008.

    PMID: 33618974
  5. 5

    Mechanical Circulatory Support With Impella Percutaneous Ventricular Assist Device as a Bridge to Recovery in Takotsubo Syndrome Complicated by Cardiogenic Shock and Left Ventricular Outflow Tract Obstruction.

    Beneduce A, Fausta Bertoldi L, Melillo F, et al.

    JACC. Cardiovascular interventions 2019; (12(4)):e31-e32 doi:10.1016/j.jcin.2018.10.046.

    PMID: 30711550
  6. 6

    Refractory Acute Myocardial Infarction Cardiogenic Shock Due to Left Ventricular Outflow Tract Obstruction.

    Akinmolayemi O, Beerkens FJ, Hu V, et al.

    JACC. Case reports 2025; (30(23)):104452 doi:10.1016/j.jaccas.2025.104452.

    PMID: 40816853
  7. 7

    Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies.

    Zakynthinos GE, Gialamas I, Tsolaki V, et al.

    Journal of cardiovascular development and disease 2024; (11(12)) doi:10.3390/jcdd11120401.

    PMID: 39728291
  8. 8

    Norepinephrine and Dobutamine-Induced Dynamic Left Ventricular Outflow Tract Obstruction Caused by Systolic Anterior Motion.

    Hung TD, Ha PVT, Chien DV

    Journal of medical cases 2024; (15(4-5)):67-71 doi:10.14740/jmc4204.

    PMID: 38715913
  9. 9

    A handicap in Takotsubo cardiomyopathy: dynamic outflow obstruction.

    Keskin M, Tanık VO, Gümüşdağ A, Yıldırımtürk Ö

    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2016; (44(2)):161-5 doi:10.5543/tkda.2015.32762.

    PMID: 27111317
  10. 10

    Takotsubo syndrome.

    Gupta S, Gupta MM

    Indian heart journal 2018; (70(1)):165-174 doi:10.1016/j.ihj.2017.09.005.

    PMID: 29455773
  11. 11

    Takotsubo Cardiomyopathy in a Case of Intracerebral Hemorrhage: A Case Report.

    Nagpal RR, Dhabhar JB, Ghanekar J

    Cureus 2019; (11(9)):e5711 doi:10.7759/cureus.5711.

    PMID: 31720179
  12. 12

    Manganese-Enhanced Magnetic Resonance Imaging in Takotsubo Syndrome.

    Singh T, Joshi S, Kershaw LE, et al.

    Circulation 2022; (146(24)):1823-1835 doi:10.1161/CIRCULATIONAHA.122.060375.

    PMID: 36317524
  13. 13

    Takotsubo Cardiomyopathy: Current Treatment.

    Madias JE

    Journal of clinical medicine 2021; (10(15)) doi:10.3390/jcm10153440.

    PMID: 34362223
  14. 14

    Takotsubo cardiomyopathy: Review of broken heart syndrome.

    Boyd B, Solh T

    JAAPA : official journal of the American Academy of Physician Assistants 2020; (33(3)):24-29 doi:10.1097/01.JAA.0000654368.35241.fc.

    PMID: 32039951
  15. 15

    Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis.

    Santoro F, Sharkey S, Citro R, et al.

    Heart (British Cardiac Society) 2024; (110(7)):476-481 doi:10.1136/heartjnl-2023-322980.

    PMID: 37666647
  16. 16

    Beta-Blockers and Long-Term Mortality in Takotsubo Syndrome: Results of the Multicenter GEIST Registry.

    Raposeiras-Roubin S, Santoro F, Arcari L, et al.

    JACC. Heart failure 2025; (13(5)):815-825 doi:10.1016/j.jchf.2024.11.015.

    PMID: 39918532

This page is for informational purposes only and does not replace professional medical advice. Always consult your cardiologist regarding your specific Takotsubo recovery timeline and medication plan.